Pulmonary hypertension in mitral valve disease: 56 surgical patients reviewed

J. M. MANNERS, J. L. MONRO, AND J. K. ROSS

From Wessex Cardiac and Thoracic Centre, Southampton Western Hospital, Southampton, UK

Manners, J. M., Monro, J. L., and Ross, J. K. (1977). Thorax, 32, 691–696. Pulmonary hypertension in mitral valve disease. A total of 392 patients have undergone prosthetic valve surgery including the mitral valve over a four-year period (1972–76). Of these patients 56 (14%) had a pulmonary artery systolic pressure of 70 mmHg or more during preoperative cardiac catheterisation and the hospital mortality of this group was 5.4%. Similarly, the hospital mortality of the remaining 336 patients with a pulmonary artery pressure below 70 mmHg was 5.4%. The presence of pulmonary hypertension in patients with valve disease including the mitral valve does not therefore indicate that the risk of dying in hospital as a consequence of corrective surgery is increased. The absence of a raised hospital mortality in this recent series may be attributed to improved surgical techniques and materials, while the use of droperidol and pentolinium which may reduce pulmonary vascular resistance as well as systemic resistance during surgery could be contributory.

Mitral valve replacement or repair are now routine operative procedures for patients with serious mitral valve disease and, with an operative mortality of 9% or less (Oparah et al., 1975; Fernandez et al., 1976; Mitha et al., 1976; Ionescu et al., 1977), provide the majority of these patients with an improved length and quality of life.

However, those patients who have developed severe pulmonary hypertension, although benefiting from mitral valve surgery, have been thought to withstand surgery less well (Emanuel and Ross, 1967; Najafi et al., 1969) and to have a higher operative mortality (Ward and Hancock, 1975). Kaul et al. (1976) have recently described a mortality of 30% in a series, collected over 10 years, of 30 patients with pulmonary hypertension undergoing mitral valve replacement, although there were no hospital deaths in the last 16 patients, while Ward and Hancock (1975) described a mortality of 56% in a small group of similar patients collected between 1961 and 1972. It would appear to be important to take the presence of pulmonary hypertension into consideration when assessing the risks of mitral valve surgery, and a review has therefore been made in the Wessex Cardiac Unit of patients with pulmonary hypertension who have undergone open mitral valve surgery.

Material and method

Records of the 1150 patients undergoing open heart procedures in a four-year period, 1972–76, were examined. Among those patients with acquired heart disease (69%), 392 who had at least the mitral valve replaced or reconstructed were studied. Of these patients, 56 (14%) with mitral valve disease were found to have pulmonary systolic pressures of 70 mmHg or more at the time of cardiac catheterisation, and this group of patients was reviewed.

The catheterisation was carried out prior to consideration for cardiac surgery. Premedication consisted of promethazine with papaveretum and hyoscine, or diamorphine and atropine, and the patients were supine and breathing air during the investigation. The relevant measurements of pulmonary and systemic pressures were made and the calculation of pulmonary vascular resistance (Wood, 1954) was carried out, using an assumed basal oxygen consumption. Arterial blood taken in the course of catheterisation was immediately analysed for oxygen and carbon dioxide tensions, using Radiometer PO₂ and PCO₂ electrodes, and latterly a Radiometer ABL 1.

At operation valve replacement was carried out using a Björk-Shiley or Starr-Edwards series 6120 prosthesis, and valve reconstruction was effected with a Carpentier ring. The ascending aorta was clamped during mitral valve procedures, the myocardial ischaemic periods not usually exceeding 20 minutes, with intermittent coronary perfusion.

The Temptrol, Harvey, or Galen bubble oxy-
genator was used for normothermic bypass. It was primed and replenished with a Ringer lactate solution, unless the packed cell volume fell below 20% during bypass, when ACD or CPD preserved bank blood, 2–4 days old, was used.

Conventional anaesthesia consisted of papaverine and hyoscine premedication, with induction using phenoperidine followed by thiopentone and pancuronium. Nitrous oxide was used to maintain anaesthesia, with 33% oxygen, and supplements of phenoperidine up to a total of 20 mg. Droperidol was used to maintain a radial artery systolic pressure below 140 mmHg before bypass and a mean arterial pressure below 90 mmHg during bypass at a flow of 2–4 l min⁻¹. If a maximum of 30 mg droperidol failed to achieve this, pentolinium in increments of 0·5 mg was given. These vasodilators were not used in the immediate postoperative period except when systemic systolic pressure exceeded 150 mmHg after adequate intravenous sedation with diazepam and papaveretum.

After bypass isoprenaline, which has now been shown to produce pulmonary vasodilatation in animals (Mentzer et al., 1976), was the catecholamine generally used if inotropic agents were required. Occasionally adrenaline or dopamine were substituted despite their adverse effect on the pulmonary vascular resistance (Polumbo and Harrison, 1972) if the pressor response to isoprenaline was insufficient, if the heart rate exceeded 100/min, or, in the case of dopamine, if the patient was oliguric with cold vasoconstricted extremities. The pulmonary artery pressure was not routinely monitored in the postoperative period although the right and left atrial and systemic pressures were measured.

After the operation all patients were ventilated with intermittent positive pressure ventilation using air and additional oxygen to produce an arterial PO₂ of 10–14 kPa (75–105 mmHg) and Pco₂ of 4·5–6 kPa (34–45 mmHg). When this regime was discontinued 40% oxygen was delivered by mask to the spontaneously breathing patient, and oxygen therapy was terminated when the arterial PO₂ was more than 10 kPa (75 mmHg) or was found to be more than 8 kPa (60 mmHg) after breathing air for 15 minutes.

Results

Over a four-year period, 56 patients with a pulmonary systolic pressure of 70 mmHg or more at the time of cardiac catheterisation underwent valve surgery, which included mitral valve replacement (55 patients) or reconstruction (1 patient), with a hospital mortality of 5·4% (Table 1). The mortality among 336 patients with a pulmonary artery pressure below 70 mmHg who also had at least the mitral valve replaced was similarly 5·4%.

Of the hypertensive group, 33 patients had only the mitral valve replaced, with two deaths, 12 patients the aortic and mitral valves with no hospital deaths, and seven patients procedures to the mitral and tricuspid valves with no deaths. In this latter group one patient had a mitral and tricuspid reconstruction with the use of Carpentier rings, two patients had mitral valve replacement and tricuspid annuloplasty, and four patients mitral and tricuspid replacement. Four patients underwent mitral, aortic, and tricuspid replacement with one hospital death.

Table 2 shows the relevant measurements and calculations at the time of cardiac catheterisation.

Table 1 Hospital mortality after mitral valve replacement

<table>
<thead>
<tr>
<th>Valve replaced</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitral</td>
<td>9</td>
<td>24</td>
<td>33</td>
</tr>
<tr>
<td>Mitral and aortic</td>
<td>5</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>Mitral and tricuspid</td>
<td>2</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Mitral, aortic and tricuspid</td>
<td>1</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>17</td>
<td>39</td>
<td>56</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pulmonary artery systolic pressure</th>
<th>Deaths</th>
<th>Less than 70 mmHg</th>
</tr>
</thead>
<tbody>
<tr>
<td>70 mmHg or more</td>
<td>No.</td>
<td>Total No. %</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>70</td>
<td>70–150</td>
</tr>
<tr>
<td>Range</td>
<td>93</td>
<td>57–90mmHg</td>
</tr>
<tr>
<td>SD</td>
<td>52</td>
<td>9–74</td>
</tr>
<tr>
<td></td>
<td>11·3</td>
<td></td>
</tr>
</tbody>
</table>

Table 2 Measurements during cardiac catheterisation
During the catheterisation these sedated and supine patients had a mean arterial oxygen tension of 7.4 kPa (55 mmHg) and arterial carbon dioxide tension of 5.1 kPa (38 mmHg).

Artificial ventilation in the postoperative period with air and added oxygen was given to all patients until the morning after the operation, but to only five patients (9%) beyond this time. Three of these patients, one of whom subsequently died, were ventilated for a further 24 hours, while one patient required ventilation from day 3 after operation for two days. One other patient, whose subsequent death was attributed to Gram-negative septicaemia, was ventilated from day 6 until death on day 9.

Three patients in this group of 56 with pulmonary hypertension died in hospital. One woman aged 60, who had aortic, mitral, and tricuspid valve replacements, died on day 9 from Gram-negative septicaemia, and her pulmonary and systolic pressures were 110 mmHg at the time of catheterisation. One 51-year-old man, who required preoperative resuscitation and artificial ventilation before proceeding to mitral valve surgery, had both a pulmonary and systemic systolic pressure of 100 mmHg and died in the operating room. One woman aged 74 years and weighing 33 kg, who died four days after mitral valve replacement from a low cardiac output, had a preoperative pulmonary systolic pressure of 70 mmHg, which was 61% of systemic systolic pressure.

Table 3 shows the relevant catheterisation data for the 11 patients who had a tricuspid procedure compared with those for the 45 patients who did not. There is no significant difference between the two groups.

Table 3 Pressure measurements during cardiac catheterisation in patients who had tricuspid procedures and in patients who did not have tricuspid procedures

<table>
<thead>
<tr>
<th></th>
<th>Tricuspid group</th>
<th>Non-tricuspid group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary artery systolic pressure (mmHg)</td>
<td>96</td>
<td>92</td>
</tr>
<tr>
<td>Pulmonary artery mean pressure (mmHg)</td>
<td>61</td>
<td>56</td>
</tr>
<tr>
<td>Systemic systolic pressure (mmHg)</td>
<td>126</td>
<td>113</td>
</tr>
<tr>
<td>Systemic mean pressure (mmHg)</td>
<td>94</td>
<td>91</td>
</tr>
<tr>
<td>Pulmonary/systemic systolic pressure %</td>
<td>75</td>
<td>81</td>
</tr>
<tr>
<td>Pulmonary/systemic mean pressure %</td>
<td>65</td>
<td>63</td>
</tr>
<tr>
<td>Pulmonary vascular resistance/m (^{-1})</td>
<td>22.7</td>
<td>18.3</td>
</tr>
</tbody>
</table>

Discussion

In the past it has been stated that extreme elevation of the pulmonary vascular resistance increases the risks of bypass surgery (Cleland et al., 1969; Najafi et al., 1969) and that the long-term prognosis is poor (Barclay et al., 1972). Publications in the earlier days of bypass surgery had shown that the overall surgical mortality for mitral valve surgery had been higher in this group of patients (Nichols et al., 1964; Hamer et al., 1968). The present survey of mitral valve operations in a four-year period has revealed that, despite the findings of severe pulmonary hypertension and a high pulmonary vascular resistance in 56 patients, the hospital mortality of 5.4% was the same as in a group of 336 consecutive patients whose pulmonary artery systolic pressure was less than 70 mmHg.

The present improved surgical results might be attributed to a spurious production of pulmonary hypertension in our patients at the time of cardiac catheterisation which did not occur in other series, to more favourable patient factors unrelated to pulmonary hypertension in this series, or to improvements in technique in the management of seriously ill patients.

During cardiac catheterisation a number of factors may influence pulmonary artery pressure and pulmonary vascular resistance (Smith and Hoffman, 1969) and these must be taken into account when assessing each patient. The present consensus is that hypoxia, hypercarbia, and catecholamines, together with reflex responses, produce vasoconstriction of lung arterioles and venules (Lee, 1971). In the group of patients we have studied the average arterial Po\(_2\) was 7.4 kPa (55 mmHg), which is higher than the level at which hypoxaemia was found to produce pulmonary vasoconstriction in animals (Rudolph and Yuan, 1966).

Arterial carbon dioxide tension was within normal limits in all but three patients and would therefore not have influenced the pulmonary circulation either by causing pulmonary vasoconstriction (Bergofsky et al., 1962) or by the increase in stroke volume and cardiac output (Prys-Roberts and Kelman, 1966) associated with hypercarbia.

The raised catecholamine level in patients with serious mitral valve disease (Chidsey et al., 1965) would seem to be one factor contributing to the production of pulmonary hypertension, merely reflecting the severity of the disease. The supine posture and therefore a further increase in lung blood-volume (Daly et al., 1964), already raised in mitral valve disease (Roy et al., 1965), was common to this group of patients and to those without pulmonary hypertension.

For these reasons the high pulmonary artery pressure in these patients seems to be related to the disease process and not simply a product of the circumstances of the cardiac catheterisation.
Calculation of pulmonary vascular resistance using an assumed basal oxygen consumption introduces a wide margin of error, but, even if the actual oxygen consumption was as much as 30% above basal, the average resistance would still exceed 10 units m⁻², while if the actual oxygen consumption was less than the assumed value the calculated resistance would be even greater.

Kirklin and Pacifico (1973) have drawn attention to the fact that in the presence of mitral incompetence the systolic wall tension is lower than would otherwise be the case. They have suggested that when there is no cardiac reserve the sudden loss of the ability of the left ventricular volume to decrease rapidly after valve replacement may contribute to a very low cardiac output. They therefore postulate that mitral valve replacement or repair might be made safer if it is advised before chronic congestive failure develops. The absence of failure as a favourable factor in this series was not apparent, but it is possible that there is a trend towards earlier operative treatment which is contributing towards lowering the mortality in patients formerly regarded as a high-risk group. The Figure illustrates that even in the patients with a very high pulmonary vascular resistance the risks of operation were not significantly greater than in the less severely affected patients.

There seems no doubt that surgical techniques and materials have improved in the last decade of cardiac surgery and that these are the major factors in the reduction of hospital mortality. The avoidance of bank blood primes for the heart–lung machine (Nahas et al., 1965), the use of filters in the bypass circuit (Hill et al., 1970), and the reduction of bank blood usage in the post-perfusion period (Ross et al., 1976) may be significant in reducing the accumulation of debris in the pulmonary vascular bed, perhaps of particular importance in the presence of pulmonary hypertension.

The use of peripheral vasodilators or ganglion-blocking drugs may also be advantageous during the postoperative period. The recent demonstration that pentolinium can reverse the pulmonary vasconstriction induced by nitrous oxide (Fahmy et al., 1976) suggests that these drugs could contribute to the successful management of patients with pulmonary hypertension. Droperidol, a drug with peripheral vasodilator activity, and pentolinium were used in this series for their systemic effect of reducing left ventricular afterload, but it is pertinent to note that droperidol reduces raised pulmonary vascular pressures (Macdonald et al., 1966) and that some ganglion-blocking agents have previously been shown to reduce pulmonary vascular resistance in mitral valve disease (Scott et al., 1955; Balchum et al., 1957). The use of nitrous oxide in this series, despite its pulmonary vasoconstrictor effect in the presence of morphine (Lappas et al., 1975), does not appear to have been detrimental, and a constrictor effect, if any, was perhaps offset by the use of phenoperidine, droperidol, and, less frequently, pentolinium.

The value of intermittent positive-pressure ventilation (IPPV) for patients after open-heart surgery, at a time when the cardiovascular system may be unstable, the residual effects of anaesthetic drugs are present, respiratory work is increased (Wilson et al., 1973), and ventilation–perfusion ratios in the lungs may be abnormal (Laver et al., 1965),...
Pulmonary hypertension in mitral valve disease: 56 surgical patients reviewed

1970), is well established. Beyond 18 hours IPPV was discontinued in the majority of patients in this series as in other patients after mitral valve surgery, based on the principles described by Humphries et al. (1973), and this suggests that increases in pulmonary blood volume and water content were not important problems for most patients postoperatively.

The continuation of oxygen therapy in the postoperative period might be thought to influence the regression of pulmonary hypertension although there seems to be no specific evidence on this point. The mean preoperative arterial Po2 was only 7-4 kPa (55 mmHg) but the improved haemodynamics which follow valve replacement would be expected to diminish pulmonary ventilation-perfusion abnormalities, increase arterial oxygen tension, and therefore minimize hypoxaemic pulmonary vasoconstriction. However, Geha et al. (1966) found that, in a group of 10 patients undergoing mitral valve replacement, the mean arterial Po2 when breathing air had risen to only 9-7 kPa (73 mmHg) two weeks after operation compared with a preoperative value of 10-1 kPa (76 mmHg), while in the differing circumstances of non-cardiac thoracic surgery, arterial Po2 was below the preoperative level even 10 to 14 days after surgery (Knudsen, 1970; Manners and Crosse, 1976).

This series of patients has not been recatheterized to determine the effects of surgery on the pulmonary circulation but there is sufficient evidence to anticipate regression of severe pulmonary hypertension after successful isolated mitral valve replacement. Braunwald et al. (1965) described a marked decline in the pulmonary arterial or right ventricular systolic pressure after mitral valve replacement in every case in a series of 31 patients with pulmonary hypertension. Dalen et al. (1967) studied five patients after mitral valve replacement and found an early fall of pulmonary artery pressure from a preoperative mean of 71 mmHg to 35 mmHg and they concluded that the presence of extreme pulmonary vascular disease did not contraindicate surgical intervention. Nine patients with a pulmonary artery systolic pressure greater than 100 mmHg were evaluated an average of 26 months after mitral valve replacement by Zener et al. (1972), when this pressure had fallen to a mean of 43 mmHg, while Kaul et al. (1976) also confirmed falls of similar magnitude 1-10 years after mitral valve replacement in all 21 survivors of their series.

Conclusions

The presence of pulmonary hypertension in patients with valve disease, including the mitral valve, does not indicate that the risk of dying in hospital as a consequence of corrective surgery is increased. Furthermore, there is sufficient evidence to anticipate that regression of severe pulmonary hypertension will take place after successful mitral valve replacement.

We are grateful to our cardiological colleagues, Drs. A. M. Johnson and N. Conway, for the cardiac catheterisation studies.

References


Requests for reprints to: Dr. J. M. Manners, Department of Anaesthetics, Southampton General Hospital, Shirley, Southampton SO9 4XY, UK.
Pulmonary hypertension in mitral valve disease: 56 surgical patients reviewed.
J M Manners, J L Monro and J K Ross

Thorax 1977 32: 691-696
doi: 10.1136/thx.32.6.691

Updated information and services can be found at:
http://thorax.bmj.com/content/32/6/691

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/